TSX:CRDL - Post Discussion
Post by
Betteryear2 on Mar 24, 2022 7:19pm
Cardiol Therapeutics Announces Year-End 2021 Update
- Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19
- Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical trial in patients with acute myocarditis
- Made strategic appointments to senior management team
- Listed on the NASDAQ stock exchange
- Ended 2021 with cash and cash equivalents of $83.9M
Oakville, Ontario--(Newsfile Corp. - March 24, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), today announces its year-end 2021 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2021. Both are available under the Company's profile on SEDAR at sedar.com and on the Company's website at cardiolrx.com.
Be the first to comment on this post